Analysts forecast that Gamida Cell Ltd (NASDAQ:GMDA) will post ($0.38) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Gamida Cell’s earnings. Gamida Cell posted earnings per share of ($0.62) during the same quarter last year, which suggests a positive year-over-year growth rate of 38.7%. The business is expected to report its next earnings results on Tuesday, May 5th.
On average, analysts expect that Gamida Cell will report full year earnings of ($1.44) per share for the current financial year. For the next year, analysts anticipate that the business will post earnings of ($1.38) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Gamida Cell.
Gamida Cell (NASDAQ:GMDA) last announced its quarterly earnings data on Tuesday, February 25th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.08.
Several analysts have recently issued reports on the stock. BMO Capital Markets lowered their price objective on shares of Gamida Cell from $19.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $19.00 price objective on shares of Gamida Cell in a research note on Tuesday, December 10th. Finally, Zacks Investment Research raised shares of Gamida Cell from a “sell” rating to a “hold” rating in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Gamida Cell presently has a consensus rating of “Buy” and an average price target of $14.80.
Hedge funds and other institutional investors have recently made changes to their positions in the company. UBS Group AG purchased a new stake in shares of Gamida Cell during the 4th quarter valued at $28,000. Royal Bank of Canada purchased a new stake in shares of Gamida Cell during the 2nd quarter valued at $71,000. Phoenix Holdings Ltd. purchased a new stake in shares of Gamida Cell during the 3rd quarter valued at $121,000. Finally, Millennium Management LLC boosted its position in Gamida Cell by 4.6% during the 3rd quarter. Millennium Management LLC now owns 69,077 shares of the company’s stock worth $299,000 after purchasing an additional 3,017 shares during the period. 22.74% of the stock is owned by institutional investors.
Shares of NASDAQ GMDA traded up $0.09 during trading on Wednesday, hitting $4.44. 10,724 shares of the company traded hands, compared to its average volume of 21,745. Gamida Cell has a 1 year low of $2.93 and a 1 year high of $13.43. The company has a 50-day moving average price of $4.60 and a 200-day moving average price of $4.47. The firm has a market capitalization of $107.55 million, a P/E ratio of -0.42 and a beta of 1.60. The company has a quick ratio of 7.60, a current ratio of 7.61 and a debt-to-equity ratio of 0.09.
Gamida Cell Company Profile
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Recommended Story: Purposes and Functions of the Federal Reserve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.